美股異動|Affirm夜盤升14.3% 第二財季營收超預期且扭虧為盈
美版“花唄”、金融科技公司Affirm(AFRM.US)夜盤升14.3%,報70.59美元。公佈2025財年第二季度業績,營收為8.66億美元,同比增長46.6%,高於市場預期的8.1億美元;意外錄得每股收益0.23美元,去年同期每股虧損0.54美元,市場預期每股虧損0.16美元。期內商品總交易量為101億美元,亦高於預期的96.4億美元。展望2025財年,Affirm目前預計商品總額將在347.4億至353.4億美元之間,營收將在31.3億至31.9億美元之間,而分析師預期分別為349.5億和31.1億美元。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.